Details of the Drug

General Information of Drug (ID: DMTAWHL)

• Drug Name: AM251
• Synonyms: AM251; 183232-66-8; AM-251; AM 251; UNII-3I4FA44MAI; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 3I4FA44MAI; CHEMBL285932; CHEBI:90724; MFCD01861181; CPD000466284; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 555.2
  Logarithm of the Partition Coefficient (xlogp); 6.5
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• Chemical Identifiers:
  Formula: C22H21Cl2IN4O
  IUPAC Name: 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
  Canonical SMILES: CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
  InChI: InChI=1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
  InChIKey: BUZAJRPLUGXRAB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2125
  ChEBI ID: CHEBI:90724
  CAS Number: 183232-66-8
  TTD ID: D08YQT

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Antagonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2)	OT3X7QG2	U5S1_HUMAN	Gene/Protein Processing	[3]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[4]
Actin-related protein 2/3 complex subunit 4 (ARPC4)	OT0ZE01B	ARPC4_HUMAN	Gene/Protein Processing	[3]
Adenylyl cyclase-associated protein 2 (CAP2)	OTC1WFNO	CAP2_HUMAN	Gene/Protein Processing	[3]
Argininosuccinate synthase (ASS1)	OT4ZMG0Q	ASSY_HUMAN	Gene/Protein Processing	[3]
Astrocytic phosphoprotein PEA-15 (PEA15)	OTKCKTSX	PEA15_HUMAN	Gene/Protein Processing	[3]
ATP-dependent RNA helicase A (DHX9)	OT5AAOQI	DHX9_HUMAN	Gene/Protein Processing	[3]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[5]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Gene/Protein Processing	[6]
cAMP-regulated phosphoprotein 21 (ARPP21)	OTWXZN5I	ARP21_HUMAN	Gene/Protein Processing	[3]

Molecular Expression Atlas of This Drug

• The Studied Disease: Discovery agent
• ICD Disease Classification: N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cannabinoid receptor 1 (CB1)	DTT	CNR1	5.59E-02	-0.22	-0.45
Cannabinoid receptor 1 (CB1)	DTT	CNR1	7.68E-01	-0.06	-0.46

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3317).
• [2] Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004 Apr;309(1):56-63.
• [3] Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 2006 Mar 20;580(7):1733-9.
• [4] Assessment of Cannabinoids Agonist and Antagonist in Invasion Potential of K562 Cancer Cells. Iran Biomed J. 2019 Mar;23(2):153-8. doi: 10.29252/.23.2.153. Epub 2018 Jun 9.
• [5] Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res. 2016 Sep;111:757-766. doi: 10.1016/j.phrs.2016.07.013. Epub 2016 Jul 14.
• [6] AM251 Suppresses Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells. PLoS One. 2016 Dec 9;11(12):e0167848. doi: 10.1371/journal.pone.0167848. eCollection 2016.